Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH

Sodium glucose cotransporter 2 (SGLT2) inhibitors, an antidiabetic drug, promotes urinary excretion of glucose by blocking its reabsorption in the renal proximal tubules. It is unclear whether SGLT2 inhibition could attenuate nonalcoholic steatohepatitis (NASH) and NASH-associated hepatocellular car...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiba, Kumiko, Tsuchiya, Kyoichiro, Komiya, Chikara, Miyachi, Yasutaka, Mori, Kentaro, Shimazu, Noriko, Yamaguchi, Shinobu, Ogasawara, Naomi, Katoh, Makoto, Itoh, Michiko, Suganami, Takayoshi, Ogawa, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799179/
https://www.ncbi.nlm.nih.gov/pubmed/29402900
http://dx.doi.org/10.1038/s41598-018-19658-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799179/
https://www.ncbi.nlm.nih.gov/pubmed/29402900
http://dx.doi.org/10.1038/s41598-018-19658-7

Ejemplares similares